dokumendiregister.ee
Sissetulev kiriAvalik

Farmakopöa töökava asjus

Ravimiamet · 24. oktoober 2025
Viit
REP-1/5616-1
Registreeritud
24. oktoober 2025
Dokumendi liik
Sissetulev kiri
Adressaat
European Directorate for the Quality of Medicines & HealthCare
Saabumis/saatmisviis
e-post
Funktsioon
REP Euroopa Farmakopöaga seotud asjaajamine
Sari
REP-1 Euroopa Farmakopöa alane kirjavahetus
Toimik
REP-1/2025
Vastutaja
Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)

Failid

Sisu (failidest)

Signe Leito Saatja: [email protected] Saatmisaeg: neljapäev, 2. oktoober 2025 15:50 Adressaat: Signe Leito Teema: Proposed addition to the work programme of Group 6: Anakinra monograph: EDQM-2025-03867-mail Järeltegevuse lipp: Järeltegevus Olekulipp: Lipuga märgitud Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Please make sure to include in any reply our mail reference: EDQM-2025-03867-mail **************************************************************************** For the attention of NPAs Copy: Presidium Dear colleagues, Please find below the link to a survey carried out concerning the proposed addition of Anakinra monograph to the work programme of Group 6: In order to have access to the survey, please copy and paste this link into your browser: https://survey.edqm.eu/index.php?r=survey/index&sid=317975&lang=en Deadline for replies: 29 October 2025 With kind regards On behalf of Dr Ola Kolaj-Robin -- Najla CHAFFAI-DABOVAL Administrative Assistant European Pharmacopoeia Department (EPD) European Directorate for the Quality of Medicines & HealthCare (EDQM) Council of Europe – Conseil de l’Europe www.edqm.eu / www.edqm.eu/hd (helpdesk) www.edqm.eu/store Follow the EDQM on: 1 Confidentiality Notice: this e-mail and any attached files may contain confidential information that is intended only for the addressee(s). If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by using the reply function and then permanently delete this e-mail (including any attached files). Thank you. **************************************************************************** Please make sure to include in any reply our mail reference: EDQM-2025-03867-mail 2
Allikas: Ravimiamet dokumendiregister →